ODF
-
BioNxt Advances ODF for Multiple Sclerosis into Human Trials with Over 40% Bioavailability Boost and Expands to Myasthenia Gravis
BioNxt Solutions Inc. is advancing its cladribine oral thin film (ODF) program, showing over 40% improved bioavailability in preclinical studies. This progress supports initiating clinical trials for Multiple Sclerosis (MS) and expanding to Myasthenia Gravis (MG), leveraging a capital-efficient strategy with an established API. The ODF platform aims to enhance patient adherence and simplify administration for chronic neurological and autoimmune conditions, targeting substantial and growing markets.
